1. Scrip
  2. >>Business

Cipla Sounds The Bugle On US Respiratory Ambition

 
• By Anju Ghangurde

One "sizeable" respiratory inhalation launch in the US every year, starting next year, is what Cipla is targeting as it expands its global franchise in the segment, though a filing this year for generic Advair isn't likely. The Indian firm also expects to sew up multiple biosimilar deals targeted at key emerging markets.

Success ladder leading to cloud and many short ones. Business, goal, competition, unique, progress, challenge, hope and leadership concept. EPS 8 vector illustration, no transparency
CIPLA IS AIMING FOR A BIGGER PLAY IN THE US RESPIRATORY SEGMENT

Cipla Ltd., which has been expanding its respiratory franchise globally, has indicated that it is revving up in the segment in the US, a market where the Indian firm has traditionally derived a smaller proportion of its overall revenues compared with some large Indian peers.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

In Brief: Sanofi Gains €10bn From Opella Sale

 
• By Sushmita Panda

Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.

Finance Watch: Biohaven Gains Up To $600m In Fresh Capital

 
• By Mandy Jackson

Public Company Edition: Biohaven secured $250m up front from Oberland Capital to support its future US troriluzole launch after pulling its EU filing. Also, Procaps arranged $130m in private equity and Rezolute grossed $96.9m in a rare follow-on offering, among other financings.

Lilly’s Ricks Urges Trump To Pick Tax Incentives Over Tariffs

 
• By Alaric DeArment

On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.